Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury

Bai, Yun; Han, Yang; Yan, Xinlong; Ren, Jing; Zeng, Quan; Li, Xiaodong; Pei, Xuetao; Han, Yan

doi:10.1016/j.bbrc.2018.04.065

Cited by 130 publications

(93 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the case of hydrogen peroxide (H 2 O 2 ), when it is provided to ASCs in culture, their secretome shows a better capability to promote cytoprotective and pro-recovery effects on fibroblasts under oxidative stress when compared to ASCs in regular culture [52]. In a case of skin flap, only the exosome fraction was used and it was observed that pre-stimulation with H 2 O 2 promoted survival and angiogenesis while reducing inflammation when compared with normal ASC secretome [53]. Due to these secretory properties, ASCs stimulated with H 2 O 2 are currently being employed in a clinical trial with patients with spinal cord injury (NCT02917291).…”

Section: Collecting Proceduresmentioning

confidence: 99%

“…Additionally, EVs could be chemically and biologically modified to broaden, alter, and/or enhance their therapeutic capability [103,105,110], the engineering of EVs becoming an emerging focus of research. The therapeutic potential of EVs has received the attention of researchers in the field of CNS pathologies such as SCI [53,84,111,112], IS [113][114][115], and PD [92,[116][117][118]. Indeed, the administration of MSC-derived exosomes could restore tissue function in multiple disease/injury models [97].…”

Section: Secretome Fractions: Where Is the Therapeutic Potential?mentioning

confidence: 99%

See 1 more Smart Citation

Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders

et al. 2020

View full text Add to dashboard Cite

Transplantation of stem cells, in particular mesenchymal stem cells (MSCs), stands as a promising therapy for trauma, stroke or neurodegenerative conditions such as spinal cord or traumatic brain injuries (SCI or TBI), ischemic stroke (IS), or Parkinson’s disease (PD). Over the last few years, cell transplantation-based approaches have started to focus on the use of cell byproducts, with a strong emphasis on cell secretome. Having this in mind, the present review discusses the current state of the art of secretome-based therapy applications in different central nervous system (CNS) pathologies. For this purpose, the following topics are discussed: (1) What are the main cell secretome sources, composition, and associated collection techniques; (2) Possible differences of the therapeutic potential of the protein and vesicular fraction of the secretome; and (3) Impact of the cell secretome on CNS-related problems such as SCI, TBI, IS, and PD. With this, we aim to clarify some of the main questions that currently exist in the field of secretome-based therapies and consequently gain new knowledge that may help in the clinical application of secretome in CNS disorders.

show abstract

Section: Collecting Proceduresmentioning

confidence: 99%

Section: Secretome Fractions: Where Is the Therapeutic Potential?mentioning

confidence: 99%

Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Similarly, it has been reported that in ex vivo rat models of skin flap exposition to ischemia/reperfusion injury, EVs derived from ADSCs improved the skin pieces survival by enhancing neovascularization inside the tissue [67]. Moreover, the authors found that preconditioning ADSCs with low doses of H 2 O 2 escalated pro-regenerative effects mediated by their EVs [67].…”

Section: Skin Diseasesmentioning

confidence: 82%

Perspectives for Future Use of Extracellular Vesicles from Umbilical Cord- and Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells in Regenerative Therapies—Synthetic Review

Lelek

Zuba‐Surma

2020

IJMS

View full text Add to dashboard Cite

Mesenchymal stem/ stromal cells (MSCs) represent progenitor cells of various origin with multiple differentiation potential, representing the most studied population of stem cells in both in vivo pre-clinical and clinical studies. MSCs may be found in many tissue sources including extensively studied adipose tissue (ADSCs) and umbilical cord Wharton’s jelly (UC-MSCs). Most of sanative effects of MSCs are due to their paracrine activity, which includes also release of extracellular vesicles (EVs). EVs are small, round cellular derivatives carrying lipids, proteins, and nucleic acids including various classes of RNAs. Due to several advantages of EVs when compare to their parental cells, MSC-derived EVs are currently drawing attention of several laboratories as potential new tools in tissue repair. This review focuses on pro-regenerative properties of EVs derived from ADSCs and UC-MSCs. We provide a synthetic summary of research conducted in vitro and in vivo by employing animal models and within initial clinical trials focusing on neurological, cardiovascular, liver, kidney, and skin diseases. The summarized studies provide encouraging evidence about MSC-EVs pro-regenerative capacity in various models of diseases, mediated by several mechanisms. Although, direct molecular mechanisms of MSC-EV action are still under investigation, the current growing data strongly indicates their potential future usefulness for tissue repair.

show abstract

“…In another study using sodium nitroprusside (SNP) as an NO donor, SNP-primed MSC microvesicles, which were enriched with Jagged-1 and Vegf-A mRNAs, were found to improve the transplantation efficacy of hematopoietic stem cells by enhancing Jagged-1 and Vegf-A expression [130]. In addition, exosomes from MSCs pre-conditioned with H 2 O 2 increased the proliferation and migration of HUVECs and improved skin flap recovery in a rat model of ischemia-reperfusion injury [131].…”

Section: Pre-conditioning Of Mscs With Biomolecules or Chemicalsmentioning

confidence: 99%

Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent

Joo

Suh

Lee

et al. 2020

IJMS

204

151

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are on the cusp of regenerative medicine due to their differentiation capacity, favorable culture conditions, ability to be manipulated in vitro, and strong immunomodulatory activity. Recent studies indicate that the pleiotropic effects of MSCs, especially their immunomodulatory potential, can be largely attributed to paracrine factors. Exosomes, vesicles that are 30-150 nanometers in diameter that function in cell-cell communication, are one of the key paracrine effectors. MSC-derived exosomes are enriched with therapeutic miRNAs, mRNAs, cytokines, lipids, and growth factors. Emerging evidences support the compelling possibility of using MSC-derived exosomes as a new form of therapy for treating several different kinds of disease such as heart, kidney, immune diseases, neural injuries, and neurodegenerative disease. This review provides a summary of current knowledge and discusses engineering of MSC-derived exosomes for their use in translational medicine.

show abstract

Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury

Cited by 130 publications

References 18 publications

Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders

Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders

Perspectives for Future Use of Extracellular Vesicles from Umbilical Cord- and Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells in Regenerative Therapies—Synthetic Review

Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent

Contact Info

Product

Resources

About